GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Compass Pathways PLC (NAS:CMPS) » Definitions » PE Ratio (TTM)

Compass Pathways (Compass Pathways) PE Ratio (TTM) : At Loss (As of Apr. 26, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Compass Pathways PE Ratio (TTM)?

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). As of today (2024-04-26), Compass Pathways's share price is $7.88. Compass Pathways's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.37. Therefore, Compass Pathways's PE Ratio (TTM) for today is At Loss.


The historical rank and industry rank for Compass Pathways's PE Ratio (TTM) or its related term are showing as below:

CMPS' s PE Ratio (TTM) Range Over the Past 10 Years
Min: At Loss   Med: At Loss   Max: At Loss
Current: At Loss



CMPS's PE Ratio (TTM) is ranked worse than
100% of 373 companies
in the Healthcare Providers & Services industry
Industry Median: 25.71 vs CMPS: At Loss

Compass Pathways's Earnings per Share (Diluted) for the three months ended in Dec. 2023 was $-0.51. Its Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.37.

As of today (2024-04-26), Compass Pathways's share price is $7.88. Compass Pathways's EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.43. Therefore, Compass Pathways's PE Ratio without NRI for today is At Loss.

Compass Pathways's EPS without NRI for the three months ended in Dec. 2023 was $-0.53. Its EPS without NRI for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.43.

Compass Pathways's EPS (Basic) for the three months ended in Dec. 2023 was $-0.51. Its EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2023 was $-2.37.


Compass Pathways PE Ratio (TTM) Historical Data

The historical data trend for Compass Pathways's PE Ratio (TTM) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Compass Pathways PE Ratio (TTM) Chart

Compass Pathways Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PE Ratio (TTM)
Get a 7-Day Free Trial N/A At Loss At Loss At Loss At Loss

Compass Pathways Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
PE Ratio (TTM) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only At Loss At Loss At Loss At Loss At Loss

Competitive Comparison of Compass Pathways's PE Ratio (TTM)

For the Medical Care Facilities subindustry, Compass Pathways's PE Ratio (TTM), along with its competitors' market caps and PE Ratio (TTM) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Compass Pathways's PE Ratio (TTM) Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Compass Pathways's PE Ratio (TTM) distribution charts can be found below:

* The bar in red indicates where Compass Pathways's PE Ratio (TTM) falls into.



Compass Pathways PE Ratio (TTM) Calculation

The PE Ratio (TTM), or Price-to-Earnings ratio, or P/E Ratio, is a financial ratio used to compare a company's market price to its Earnings per Share (Diluted). It is the most widely used ratio in the valuation of stocks.

Compass Pathways's PE Ratio (TTM) for today is calculated as

PE Ratio (TTM)=Share Price/Earnings per Share (Diluted) (TTM)
=7.88/-2.365
=At Loss

Compass Pathways's Share Price of today is $7.88.
Compass Pathways's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.37.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PE Ratio (TTM)=Market Cap /Net Income

There are at least three kinds of PE Ratio (TTM)s used by different investors. They are Trailing Twelve Month PE Ratio (TTM) or PE Ratio (TTM) (TTM), Forward PE Ratio, or PE Ratio without NRI. A new PE Ratio (TTM) based on inflation-adjusted normalized PE Ratio (TTM) is called Shiller PE Ratio, after Yale professor Robert Shiller.

In the calculation of PE Ratio (TTM), the earnings per share used are the earnings per share over the past 12 months. For Forward PE Ratio, the earnings are the expected earnings for the next twelve months. In the case of PE Ratio without NRI, the reported earnings less the non-recurring items are used.

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. Since it looks at the average over the last 10 years, Shiller PE Ratio is also called PE10.


Compass Pathways  (NAS:CMPS) PE Ratio (TTM) Explanation

The PE Ratio (TTM) can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. For example, if a company earns $2 a share per year, and the stock is traded at $30, the PE Ratio (TTM) is 15. Therefore it takes 15 years for the company to earn back the $30 you paid for its stock, assuming the earnings stays constant over the next 15 years.

In real business, earnings never stay constant. If a company can grow its earnings, it takes fewer years for the company to earn back the price you pay for the stock. If a company's earnings decline it takes more years. As a shareholder, you want the company to earn back the price you pay as soon as possible. Therefore, lower P/E stocks are more attractive than higher P/E stocks so long as the PE Ratio (TTM) is positive. Also for stocks with the same PE Ratio (TTM), the one with faster growth business is more attractive.

If a company loses money, the PE Ratio (TTM) becomes meaningless.

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the PE Ratio (TTM) divided by the growth ratio. He thinks a company with a PE Ratio (TTM) equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a PE Ratio (TTM) of 20, instead of a company growing 10% a year with a PE Ratio (TTM) of 10.

Because the PE Ratio (TTM) measures how long it takes to earn back the price you pay, the PE Ratio (TTM) can be applied to the stocks across different industries. That is why it is the one of the most important and widely used indicators for the valuation of stocks.

Similar to the PE Ratio without NRI or PS Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PE Ratio (TTM) measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

Investors need to be aware that the PE Ratio (TTM) can be misleading a lot of times, especially when the underlying business is cyclical and unpredictable. As Peter Lynch pointed out, cyclical businesses have higher profit margins at the peaks of the business cycles. Their earnings are high and PE Ratio (TTM)s are artificially low. It is usually a bad idea to buy a cyclical business when the PE Ratio (TTM) is low. A better ratio to identify the time to buy a cyclical businesses is the PS Ratio .

PE Ratio (TTM) can also be affected by non-recurring-items such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio (TTM).


Compass Pathways PE Ratio (TTM) Related Terms

Thank you for viewing the detailed overview of Compass Pathways's PE Ratio (TTM) provided by GuruFocus.com. Please click on the following links to see related term pages.


Compass Pathways (Compass Pathways) Business Description

Traded in Other Exchanges
Address
33 Broadwick Street, London, GBR, W1F 0DQ
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find better ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.
Executives
Ekaterina Malievskaia officer: Chief Innovation Officer C/O COMPASS PATHWAYS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
George Jay Goldsmith director, 10 percent owner, officer: Chief Executive Officer C/O COMPASS PATHWAYS PLC, 1 ASHLEY ROAD, 3RD FLOOR, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Mary-rose Hughes officer: Interim CFO C/O COMPASS PATHWAYS PLC, 33 BROADWICK STREET, LONDON X0 W1F0DQ
Daphne Karydas director 35 GATEHOUSE DRIVE, BUILDING D, FLOOR 3, WALTHAM MA 02451
Kabir Nath director, officer: Chief Executive Officer C/O COMPASS PATHWAYS PLC, 33 BROADWICK STREET, LONDON X0 W1F 0DQ
Annalisa Jenkins director C/O ARDELYX, INC., 34715 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
David Y Norton director 8 GREENHOLM STREET, APT C, PRINCETON NJ 08540
Matthew A Owens officer: General Counsel & CLO 1900 POLARIS PARKWAY, COLUMBUS OH 43240
Atai Life Sciences Ag 10 percent owner KRAUSENSTRASSE 9-10, BERLIN 2M 10117
Atai Life Sciences N.v. 10 percent owner 524 BROADWAY, NEW YORK NY 10013
Linda Mcgoldrick director C/O AVADIM HEALTH, INC., 81 THOMPSON STREET, ASHEVILLE NC 28803
Jason Camm director C/O ATAI LIFE SCIENCES N.V., 180 VARICK STREET, NEW YORK NY 10014
Robert Mcquade director C/O COMPASS PATHWAYS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT
Michael Falvey officer: Chief Financial Officer C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, 2ND FLOOR, NEWTON MA 02459
Guy Goodwin officer: Chief Medical Officer C/O COMPASS PATHWAYS PLC, 3RD FLOOR, 1 ASHLEY ROAD, ALTRINCHAM, CHESHIRE X0 WA14 2DT